Clinical Trial

Corticosteroids to Treat Pancreatitis

Study acronym: CRISP
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-07; most recent amendment 2026-02-16.
Status change: Not Yet Recruiting → Recruiting 2022-11-29
Trial Details
NCT Number NCT05160506
Lead Sponsor Beth Israel Deaconess Medical Center
Conditions Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Enrollment 86 participants
Start Date 2022-03-06
Primary Completion 2027-01 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-18